41 results about "Angiogenic Process" patented technology

Q is —N=or CR2 X is S, O or NOR3 Y is —O—, —S—, —SO— or —SO2—R and R1 are each, independently, H, a substituted or unsubstituted aliphatic, aromatic, heteroaromatic or aralkyl groupR2 is H or a substituentR3 is H, or —C(O)R4 R4 is a substituted or unsubstituted aliphatic or aromatic groupn is an integer from 0 to 1Chemical compounds having structural formula I and physiologically acceptable salts thereof, are inhibitors of serine / threonine and tyrosine kinase activity. Several of the tyrosine kinases, whose activity is inhibited by these chemical compounds, are involved in angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyperproliferative disorders.

The present invention d ribs novel compounds of the formula: useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

There is provided a simplified and inexpensive method for the in-vitro identification, isolation and culture of human vasculogenic progenitor cells. The method and the progenitor cells isolated thereby can be used for in-vitro vascular engineering, treatment of congenital and acquired vascular and hematological abnormalities, for evaluation and development of drugs affecting vasculo- and angiogenic processes, and for further investigation into tissue differentiation and development.

The present invention relates to chemical compounds having a general formula Iwherein A, B, D, E, G, H1-5 and R1-4 are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of these kinases. For example, the compounds are capable of modulating kinase enzymes thereby influencing the process of angiogenesis and treating angiogenesis-related diseases and other poliferative disorders, including cancer and inflammation. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of protein kinases.

Chemical compounds having structural formula Iand physiologically acceptable salts thereof, are inhibitors of serine / threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disase states where angiogenesis or endothelial cell hyperproliferaton is a factor. These compounds can be used to treat cancer, hyperproliferative disorders, rheumatoid artheritis, disorders of the immune system, transplant rejection, and inflammatory disorders.

There is provided a simplified and inexpensive method for the in-vitro identification, isolation and culture of human vasculogenic progenitor cells. The method and the progenitor cells isolated thereby can be used for in-vitro vascular engineering, treatment of congenital and acquired vascular and hematological abnormalities, for evaluation and development of drugs affecting vasculo- and angiogenic processes, and for further investigation into tissue differentiation and development.

A simplified and inexpensive method for the in-vitro identification, isolation and culture of human vasculogenic progenitor cells is provided. The method and the progenitor cells provided herein can be used for in-vitro vascular engineering, treatment of congenital and acquired vascular and hematological abnormalities, for evaluation and development of drugs affecting vasculo- and angiogenic processes, and for further investigation into tissue differentiation and development.

Nucleotide sequences and the corresponding polypeptide sequences implicated in the regulation of angiogenesis are identified. The nucleotide and polypeptide sequences, or pharmaceutical compositions made from such sequences, can be used in the clinical study of the angiogenesis process, the prognosis, diagnosis and treatment of pathologies linked to angiogenesis, and in the implementation of pharmacological, pharmacogenomic and drug identification trials.

This invention provides for the use of compounds represented by the structure of the general formula (A):wherein L is a lipid or a phospholipid, Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol, Y is either nothing or a spacer group ranging in length from 2 to 30 atoms, X is a physiologically acceptable monomer, dimer, oligomer, or polymer, wherein X is a glycosaminoglycan; and n is a number from 2 to 1000, wherein any bond between L, Z, Y and X is either an amide or an esoteric bond in treating a subject suffering from a disease associated with harmful angiogenic processes such as cancer.

The present invention relates to a pharmaceutical composition and method for treating and preventing musculoskeletal and connective tissue diseases of unknown etiology, such as different forms of arthritis and other rheumatic conditions, comprising a combination of therapeutic agents that improve the processes of blood circulation and angiogenesis in the affected tissues, as well as other supporting therapies. Among the components of herein proposed pharmaceutical composition, are: vitamin K, polyunsaturated fatty acids (blood thinner), and niacin (vasodilator and hypolipidemic agent).

The site-specific expression of selectins on endothelial cells of blood vessels during angiogenesis provides an opportunity to target anti-cancer drugs to the vascular endothelium to extend the range of the therapeutic effect. This invention describes an innovative drug targeting strategy for the selective delivery of the anticancer drugs to endothelial cells by means of polymer-drug conjugates modified with a carbohydrate ligand for the vascular selectins. A model chemotherapeutic drug, doxorubicin, and the E-selectin ligand, sLex, are attached to a biocompatible polymer (HPMA). The selective binding, cellular uptake, intracellular fate, and cell cytotoxicity of the polymer-bound drug are investigated in human endothelial cells.

The invention relates to indolone compounds shown as a general formula (a) or derivatives thereof and applications thereof. According to the invention, indolone compounds are substituted with deuterium to obtain deuterium-enriched indolone compounds; the indolone compounds can simultaneously act on the following three key receptor families involved in angiogenesis process: vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR), so as to inhibit angiogenesis and achieve the effect of treating cancers. The deuterated indolone compounds or the derivatives thereof have the advantage of high efficiency when used asdrugs. The general formula (a) is as shown in the specification.

The present invention provides a compound of formula (I), wherein Q is -N= or CR2; X is S, O or NOR3; Y is -O-, S-, -SO- or -SO2-; R and R1 are independently is H, substituted or unsubstituted aliphatic, aromatic, heteroaromatic or aralkyl-yl; group; R2 is H or a substituent; R3 is H, or -C(O)R4; R4 is substituted or unsubstituted Substituted aliphatic or aromatic groups; n is an integer 0-1. Compounds of formula (I) and their physiologically acceptable salts are inhibitors of serine / threonine and tyrosine kinase activity. Several tyrosine kinases whose activity can be inhibited by these compounds are involved in the angiogenic process. Thus, these chemical compounds are able to ameliorate disease states in which angiogenesis or endothelial cell proliferation is a factor. These compounds are useful in the treatment of cancer and hyperproliferative diseases.

Multifunctional and multivalent angiogenesis inhibitors are made up of fusion proteins comprising a polypeptide which recognizes and blocks a functionally active region of a molecule involved in the angiogenesis process and a polypeptide comprising an oligomerization domain and functionally active, inhibitor or modulator region of the angiogenesis process, separated by a proteinase-sensitive region. These inhibitors are applicable in treating and preventing pathologies occurring with angiogenesis process, for example cancer, rheumatic arthritis or psoriasis.

The present invention relates to a pharmaceutical composition and method for treating and preventing musculoskeletal and connective tissue diseases of unknown etiology, such as different forms of arthritis and other rheumatic conditions, comprising a combination of therapeutic agents that improve the processes of blood circulation and angiogenesis in the affected tissues, as well as other supporting therapies. Among the components of herein proposed pharmaceutical composition, are: vitamin K, polyunsaturated fatty acids (blood thinner), and niacin (vasodilator and hypolipidemic agent).

A simplified and inexpensive method for the in-vitro identification, isolation and culture of human vasculogenic progenitor cells is provided. The method and the progenitor cells provided herein can be used for in-vitro vascular engineering, treatment of congenital and acquired vascular and hematological abnormalities, for evaluation and development of drugs affecting vasculo- and angiogenic processes, and for further investigation into tissue differentiation and development.

This invention provides isolated nucleic acid and amino acid sequences encoding VG5Q, a novel angiogenic growth factor protein with pro-angiogenic activity, a forkhead-associated domain, a G-patch domain; characteristic subcellular localization in an in vitro Matrigel model of angiogenesis: towards the cell periphery in early stages of tubulogenesis, between cells in newly formed endothelial tubes, and no nuclear staining after 24 hours; is expressed in endothelial cells; is secreted during angiogenesis; and interacts with TWEAK. The invention also provides for expression vectors containing nucleic acid sequences encoding VG5Q protein, and host cells containing one or more expression vectors for the recombinant expression of VG5Q. The invention also provides for methods of using VG5Q for the diagnosis and treatment of angiogenesis-mediated diseases or disorders.

The present invention describes novel compounds of the formula:(Q)d-Ln-Ch,useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention also provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention also provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

Chemical compounds having structural formula Iand physiologically acceptable salts thereof, are inhibitors of serine / threonine and tyrosine kinase activity. Several of the tyrosine kinases, whose activity is inhibited by these chemical compounds, are involved in angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyperproliferative disorders.

The present invention provides a protein having a potent cell-death inducing activity that is, a fused protein is in which a modified Bax protein fused with GFP at the N-terminus and is further fused with a homing signal peptide having a homing activity specific for endothelial cells in tumor angiogenesis; a gene coding the fused protein; and a cancer cell growth inhibitor containing the fused protein. Namely, a fused gene containing a cell death-inducing gene acting specially on cancer tissue, which is a fused gene having a gene encoding a homing signal peptide sequence specific for endothelial cells undergoing angiogenesis, a gene encoding a green fluorescent protein (GFP) and a gene encoding ΔNBax protein, which is human Bax with a deletion of the N-terminal sequence containing the BH3 domain in this order, and a fusion protein encoded by the fused gene.

The present invention describes novel kits and compositions comprising compounds of the formula (I): (Q)d-Ln-Ch, useful for the diagnosis and treatment of cancer in combination therapy in a patient. The present invention provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.

The present invention relates to methods of inducing or inhibiting the angiogenic process and promoting vessel growth or stabilization in an organ by modulating the trk receptor pathway. The present invention also relates to a method for treating a pathological disorder in a patient which includes administering a trk receptor ligand or an inhibitor or expression or activity of a trk receptor ligand. The present invention also relates to a method of screening for a modulator of angiogenesis, vessel growth, or vessel stabilization. Another aspect of the present invention is a method of diagnosing or monitoring a pathological disorder in a patient which includes determining the presence or amount of a trk receptor ligand or activation of a trk receptor ligand in a biological sample.

The invention relates to the field of medicine, in particular to angiogenesis agonist polypeptide, namely, polypeptide capable of treating ischemic diseases. The angiogenesis agonist polypeptide is characterized in that the sequence of the polypeptide is a brand-new sequence, and the angiogenesis agonist polypeptide has the function of promoting angiogenesis. The angiogenesis agonist polypeptide is used for cerebral arterial thrombosis. The angiogenesis agonist polypeptide has the advantages that the angiogenesis agonist polypeptide is novel micro-molecule polypeptide screened out of cytomembrane surface receptor sequence protein which has the sequence of GPR124 and has angiogenesis activity, the polypeptide sequence can combine specificity and integrin, adhesion and transfer of cells in the angiogenesis process are adjusted, and therefore the function of treating the ischemic disease is achieved. Potential new medicine development value is achieved.

The use in the medical-surgical field of biomaterials based on hyaluronic acid derivatives, optionally in association with natural, synthetic or semisynthetic biopolymers, for suppressing the angiogenic process associated with tumour proliferation (in primary and secondary tumours) is disclosed.

The invention relates to a novel synergetic medical compound being capable of suppressing growth of tumors, which consists of an enediyne drug and an alkylated chemotherapeutic drug, i.e. lidamycin and temodar; relevant researches prove that the medical compound can synergetically resist the multiplication of the tumor cells, induce apoptosis and suppress angiogenesis; in vivo test has an obvious curative effect on nude mice transplanted tumor of the human neuroglioma U87 cells. The medical compound has an enhanced function of suppressing the growth of tumors and angiogenesis in tumor tissues, thus displaying a synergetic tumor suppressing effect and having good application prospect.

The invention provides an application of a composite of sweet wormwood herb and turtle shell in preparing antitumor medicine. The composite comprises five traditional Chinese medicines, namely sweet wormwood herb, Colla Carapacis Trionycis, rehmanniae, rhizoma anemarrhenae and Tree peony bark, and preparation form thereof is solid. The composite provided by the invention has activity in antitumorchronic inflammation reaction, can be used for treating tumor inflammation reaction and angiogenesis process, and can be used as adjuvant therapy medicine and increase antitumor therapy of chemotherapeutics. The invention utilizes the theoretical background that tumors can generate various cells and cytokines by inducing under hypoxia microenvironment, researches and illustrates the miracle performance of traditional Chinese medicine, namely entering into collaterals for eliminating pathogens and leading pathogens out, provides important accordance for exploring new clinical value of famous and high-quality traditional Chinese medicine recipe, and points out new and important direction for developing traditional Chinese medicine theory.

The invention provides an application of a composite of sweet wormwood herb and turtle shell in preparing antitumor medicine. The composite comprises five traditional Chinese medicines, namely sweet wormwood herb, Colla Carapacis Trionycis, rehmanniae, rhizoma anemarrhenae and Tree peony bark, and preparation form thereof is solid. The composite provided by the invention has activity in antitumor chronic inflammation reaction, can be used for treating tumor inflammation reaction and angiogenesis process, and can be used as adjuvant therapy medicine and increase antitumor therapy of chemotherapeutics. The invention utilizes the theoretical background that tumors can generate various cells and cytokines by inducing under hypoxia microenvironment, researches and illustrates the miracle performance of traditional Chinese medicine, namely entering into collaterals for eliminating pathogens and leading pathogens out, provides important accordance for exploring new clinical value of famous and high-quality traditional Chinese medicine recipe, and points out new and important direction for developing traditional Chinese medicine theory.

An expandable stent (1) to enhance the supply of blood to downstream tissue which is being supplied with blood through a diseased intracranial artery (100) with a stenosis (102) formed therein by plaque with a bore (103) therethrough. The expandable stent (1) comprises first and second end portions (3,4) joined by a central portion (5). The central portion (5) is configured in the expanded state of the stent (1) to be 10 located in the bore (103) of the stenosis (102) with the first and second end portions (3,4) abutting non- diseased parts (104,106) of the artery (100) adjacent the proximal and distal ends (105,107) of the stenosis (102) for anchoring the stent (1) in the artery (100). The central portion (5) with the stent (1) in the expanded state is configured to apply a radial outwardpressure to the stenosis (102) such that the diameter of the bore (103) of the stenosis (102) is maintained at its current diameter or increased to 15 approximately 50% of the non-diseased parts (104,106) of the artery (100).

The present invention relates to methods of inducing or inhibiting the angiogenic process and promoting vessel growth or stabilization in an organ by modulating the trk receptor pathway. The present invention also relates to a method for treating a pathological disorder in a patient which includes administering a trk receptor ligand or an inhibitor or expression or activity of a trk receptor ligand. The present invention also relates to a method of screening for a modulator of angiogenesis, vessel growth, or vessel stabilization. Another aspect of the present invention is a method of diagnosing or monitoring a pathological disorder in a patient which includes determining the presence or amount of a trk receptor ligand or activation of a trk receptor ligand in a biological sample.

The present invention relates to methods of inducing or inhibiting the angiogenic process and promoting vessel growth or stabilization in an organ by modulating the trk receptor pathway. The present invention also relates to a method for treating a pathological disorder in a patient which includes administering a trk receptor ligand or an inhibitor or expression or activity of a trk receptor ligand. The present invention also relates to a method of screening for a modulator of angiogenesis, vessel growth, or vessel stabilization. Another aspect of the present invention is a method of diagnosing or monitoring a pathological disorder in a patient which includes determining the presence or amount of a trk receptor ligand or activation of a trk receptor ligand in a biological sample.